Von Willebrand Factor, Plasminogen Activator Inhibitor-1 and C-Reactive Protein Are Markers of Thrombolytic Efficacy in Acute Myocardial Infarction

Summary

Plasma von Willebrand factor, plasminogen activator inhibitor activity and C-reactive protein were assessed as markers of coronary recanalisation in 30 patients with acute myocardial infarction receiving tissue-type plasminogen activator (t-PA). Blood samples were taken before t-PA (time 0), 4-hourly for 24 h and daily up to 72 h. A continuous electrocardiogram was recorded in the first 24 h. Coronary arteriography was performed 90 min and 24 h after the start of t-PA. Patients with a patent infarct artery (n = 17), compared to those with occluded artery (n = 13), showed a fall in von Willebrand factor from 0 to 24 h (p = 0.001), a greater fall in plasminogen activator inhibitor from 24 to 48 h (p = 0.04) and a fall in C-reactive protein from 48 to 72 h (p = 0.002). The accuracy of these indices compared favourably with time to peak plasma MB creatine kinase and ≥ 50% resolution of maximal ST-deviation on the electrocardiogram.

Thus, changes in plasma von Willebrand factor, plasminogen activator inhibitor and C-reactive protein during the first 3 days of myocardial infarction are indicative of thrombolytic efficacy. Their concordant behaviour may reflect a common regulatory mechanism.

• REFERENCES

• 1 Simoons ML, Serruys PW, van den Brand M. et al Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. J Am Coll Cardiol 1986; 7: 717-728
• 2 Hochman JS, Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 1987; 75: 299-306
• 3 Res JC, Simoons ML, van der Wall EE. et al Long term improvement in global left ventricular function after early thrombolytic treatment in acute myocardial infarction. Br Heart J 1986; 56: 414-421
• 4 Anderson JL, Marshall HW, Bray BE. et al A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. N Engl J Med 1983; 308: 1312-1318
• 5 Bell D, Jackson M, Nicoll JJ, Millar A, Dawes J, Muir AL. Inflammatory response, neutrophil activation, and free radical production after acute myocardial infarction: effect of thrombolytic treatment. Br Heart J 1990; 63: 82-87
• 6 Andreotti F, Roncaglioni MC, Hackett DR. et al Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990; 16: 1553-1560
• 7 Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz JK. The Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. N Engl J Med 1985; 312: 1073-1078
• 8 Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto miocardico (GISSI) Effectiveness of intravenous thrombolytic treamtent in acute myocardial infarction. Lancet 1986; i: 397-402
• 9 Smalling RW, Fuentes F, Freund GC. et al Beneficial effects of intracoronary thrombolysis up to 18 h after the onset of pain in evolving myocardial infarction. Am Heart J 1982; 104: 912-920
• 10 De Feyter PJ, van Eenige MJ, van der Wall EE. et al Effects of spontaneous and streptokinase-induced recanalization on left ventricular function after myocardial infarction. Ciculation 1983; 67: 1039-1044
• 11 Armstrong PW, Baigrie RS, Daly PA. et al Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. J Am Coll Cardiol 1989; 13: 1469-1476
• 12 Beebe DP, Aronson DL. An automated fibrinolytic assay performed in micro titer plates. Thromb Res 1987; 47: 123-128
• 13 The TIMI Study Group The thrombolysis in myocardial infarction (TIMI) trial: phase 1 findings. N Engl J Med 1984; 33: 523-530
• 14 Ingerslev J. A sensitive ELISA for von Willebrand factor (vWf: Ag). Scand J Clin Lab Invest 1987; 47: 143-149
• 15 Verheijen JH, Chang GTG, Kluft C. Evidence for the occurence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
• 16 Gaffney P, Curtis AD. A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
• 17 Hogg KJ, Hornung RS, Howie CA, Hockings N, Dunn FG, Hillis WS. Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: use of the ST segment as a non-invasive marker. Br Heart J 1988; 60: 275-280
• 18 Bossi M, Matta F. GISSI: Valutazione delle curve enzimatiche. G Ital Cardiol 1987; 17: 45-56
• 19 Mauri F, Gasparini M, Barbonaglia L. Criteri non invasivi di avvenuta riperfusione dopo thrombolisi. In: Cardiologia 87. Atti del XXI Corso di Aggiornamento, Centro A. De Gasperis. Rovelli F. (ed) Edizioni Librex: Milan: 1987. pp 35-46
• 20 Cucuianu MP, Missits I, Olinic N, Roman S. Increased ristocetin-cofactor in acute myocardial infarction: a component of the acute phase reaction. Thromb Haemostas 1980; 43: 41-44
• 21 Margulis T, David M, Maor N. et al The von Willebrand factor in myocardial infarction and unstable angina: a kinetic study. Thromb Haemostas 1986; 55: 366-368
• 22 Kluft C, Verheijen JH, Jie AFH. et al The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605-610
• 23 Gram J, Kluft C, Jespersen J. Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI). Thromb Haemostas 1987; 58: 817-821
• 24 de Beer FC, Hind CRK, Fox KM, Allan RM, Maseri A, Pepys M. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982; 47: 239-243
• 25 Dinarello CA. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med 1984; 311: 1413-1418
• 26 Schorer AE, Moldow CF, Rick ME. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells. Br J Haematol 1987; 67: 193-197
• 27 Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Loskutoff DL. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988; 263: 5797-5803
• 28 van den Berg EA, Sprengers ED, Jaye M, Burgess W, Maciag T, van Hinsbergh VWM. Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells. Thromb Haemostas 1988; 60: 63-67
• 29 Maury CPJ, Teppo AM. Circulating tumour necrosis factor-α (cachectin) in myocardial infarction. J Intern Med 1989; 225: 333-336
• 30 Ranjadayalan K, Umachandran V, Davies Sw, Syndercombe-Court D, Gutteridge CN, Timmis AD. Thrombolytic treatment in acute myocardial infarction: neutrophil activation, peripheral leucocyte responses, and myocardial injury. Br Heart J 1991; 66: 10-14
• 31 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17, 187 cases of acute myocardial infarction. ISIS-2. Lancet 1988; ii: 349-360
• 32 Yusuf S, Collins R, Peto R. et al Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results of mortality, reinfarction and side-effects from 33 randomised controlled trials. Eur Heart J 1985; 6: 556-585
• 33 Ellis SG, O’Neill WW, Bates ER, Walton JA, Nabel EG, Topol EJ. Coronary angioplasty as primary therapy for acute myocardial infarction 6 to 48 hours after symptom onset: report of an initial experience. J Am Coll Cardiol 1989; 13: 1122-1126
• 34 Rapaport E. Early versus late opening of coronary arteries: the effect of timing. Clin Cardiol 1990; 13: VIII-18-VIII-22